AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
📊 AbbVie generated approximately $61.2 billion in revenue for FY 2025, representing an 8.6% increase from the prior year.
💰 The company reported net income of about $4.2 billion with a net margin of roughly 6.9%.
⚠️ AbbVie's balance sheet shows a debt-to-equity ratio of -21.1x, indicating total liabilities exceed shareholder equity.
📉 Despite high leverage, the firm generated nearly $17.8 billion in free cash flow during FY 2025.
🏥 Pfizer operates as a diversified global leader with manufacturing sites serving patients in roughly 200 countries.
💵 Pfizer reported revenue of nearly $62.6 billion for FY 2025, a slight decline of 1.6% from the previous year.
📈 The company achieved net income close to $7.8 billion with a net margin of approximately 12.4%.
🛡️ Pfizer's balance sheet displays a debt-to-equity ratio of 0.8x and a current ratio of roughly 1.2x.
🏭 AbbVie relies heavily on three major wholesale distributors for nearly all its pharmaceutical sales in the United States.
💊 Two major products currently account for nearly 42% of AbbVie's total revenue, creating concentration risk.
⚠️ Pfizer faces significant patent expirations between 2026 and 2030 that could lead to substantial revenue reductions.
📉 Pfizer's high dividend yield reflects investor concerns about its future growth and ability to sustain payouts.
🧬 AbbVie is navigating the loss of exclusivity on Humira while growing revenue with Skyrizi and Rinvoq.
🔍 Analysts suggest Pfizer appears more affordable based on Forward P/E and P/S ratios compared to AbbVie.
🎯 A conservative investor perspective favors AbbVie for its stronger growth outlook and predictable business performance.
📉 The Motley Fool Stock Advisor team recently identified 10 best stocks to buy, but AbbVie was not included in the list.
- AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue.
- In FY 2025, AbbVie revenue reached approximately $61.2 billion, representing an increase of nearly 8.6% from the prior year.
- The company reported net income of about $4.2 billion for FY 2025, resulting in a net margin of roughly 6.9% as it integrated newer products.
- Despite a debt-to-equity ratio exceeding equity, AbbVie generated free cash flow of nearly $17.8 billion in FY 2025.
- AbbVie has successfully offset the decline in Humira revenue with growth from Skyrizi and Rinvoq, demonstrating its ability to develop new medications.
- The company maintains consistent dividend payments to shareholders, providing reliable income for investors.
- AbbVie is characterized as having a stronger growth outlook and more predictable business performance compared to competitors.
- AbbVie's debt-to-equity ratio is -21.1x as of December 2025, indicating total liabilities significantly exceed shareholder equity.
- The company's current ratio stands at approximately 0.7x, suggesting potential difficulty in meeting short-term obligations with short-term assets.
- AbbVie faces significant revenue concentration risk, with two major products accounting for nearly 42% of its 2025 revenue.
- The company is vulnerable to intensifying competition from biosimilars and pricing pressures stemming from the Inflation Reduction Act.
- Complex biologics manufacturing exposes AbbVie to supply chain disruptions and single-source supplier issues.
- Pfizer expects a significant revenue reduction as several key patents expire between 2026 and 2030.
- Pfizer faces stiff competition from generic manufacturers and other pharmaceutical giants like Merck and Johnson & Johnson.
- Pfizer must manage cybersecurity risks and the high costs associated with potentially unsuccessful research and development projects.
- Pfizer's higher dividend yield may reflect investor concerns about the company's future growth and ability to sustain dividend payments.
- AbbVie was not included in The Motley Fool Stock Advisor analyst team's list of 10 best stocks for investors to buy now.
